$-0.12 EPS Expected for Cerus Corporation (CERS)

April 17, 2018 - By Rusty Cady

Investors sentiment increased to 1.45 in 2017 Q4. Its up 0.13, from 1.32 in 2017Q3. It improved, as 6 investors sold Cerus Corporation shares while 25 reduced holdings. 14 funds opened positions while 31 raised stakes. 58.96 million shares or 2.97% more from 57.26 million shares in 2017Q3 were reported.
Metropolitan Life Insurance has 26,314 shares. American Intll Grp stated it has 0% in Cerus Corporation (NASDAQ:CERS). Price T Rowe Md holds 0% or 81,000 shares in its portfolio. Manufacturers Life Ins Company The holds 91,141 shares. Ohio-based Budros Ruhlin And Roe has invested 0.01% in Cerus Corporation (NASDAQ:CERS). Art Advsr Ltd Liability Corp has 0.03% invested in Cerus Corporation (NASDAQ:CERS). Geode Capital Mngmt Lc has 0% invested in Cerus Corporation (NASDAQ:CERS) for 990,324 shares. First Midwest Financial Bank Tru Division, Illinois-based fund reported 784,416 shares. Bnp Paribas Arbitrage Sa reported 25,408 shares. Deutsche Bancorp Ag owns 0% invested in Cerus Corporation (NASDAQ:CERS) for 267,051 shares. 37,152 are held by Teacher Retirement Systems Of Texas. D E Shaw Communications Incorporated owns 668,595 shares. Proshare Ltd Llc stated it has 78,274 shares. Raub Brock Cap Management Limited Partnership has invested 0.02% in Cerus Corporation (NASDAQ:CERS). Envestnet Asset Mngmt Incorporated has 5,377 shares for 0% of their portfolio.

Since March 10, 2018, it had 1 buy, and 5 selling transactions for $597,723 activity. Green Kevin Dennis had sold 4,737 shares worth $23,409 on Saturday, March 10. CORASH LAURENCE M had bought 150,011 shares worth $773,199 on Monday, March 12. 17,766 shares valued at $87,795 were sold by Greenman William Mariner on Saturday, March 10. The insider Moore Carol sold 4,686 shares worth $23,151. The insider Benjamin Richard J sold 3,680 shares worth $18,328.

Analysts expect Cerus Corporation (NASDAQ:CERS) to report $-0.12 EPS on May, 2.They anticipate $0.06 EPS change or 33.33 % from last quarter’s $-0.18 EPS. After having $-0.10 EPS previously, Cerus Corporation’s analysts see 20.00 % EPS growth. The stock decreased 0.56% or $0.03 during the last trading session, reaching $5.35. About 463,913 shares traded. Cerus Corporation (NASDAQ:CERS) has risen 26.07% since April 17, 2017 and is uptrending. It has outperformed by 14.52% the S&P500.

Cerus Corporation (NASDAQ:CERS) Ratings Coverage

Among 2 analysts covering Cerus Corp (NASDAQ:CERS), 2 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Cerus Corp had 5 analyst reports since October 30, 2017 according to SRatingsIntel. The rating was maintained by Robert W. Baird on Monday, October 30 with “Buy”. The company was maintained on Thursday, November 30 by Robert W. Baird. Cantor Fitzgerald maintained Cerus Corporation (NASDAQ:CERS) on Monday, January 8 with “Buy” rating. The stock of Cerus Corporation (NASDAQ:CERS) earned “Buy” rating by Robert W. Baird on Wednesday, January 24. Cantor Fitzgerald maintained Cerus Corporation (NASDAQ:CERS) on Thursday, March 8 with “Buy” rating.

Cerus Corporation, a biomedical products company, focuses on developing and commercializing the INTERCEPT Blood System to enhance blood safety. The company has market cap of $693.34 million. The Company’s INTERCEPT Blood System is based on its proprietary technology for controlling biological replication; and targets and inactivates blood-borne pathogens, such as viruses, bacteria, and parasites, as well as harmful white blood cells, while preserving the therapeutic properties of platelet, plasma, and red blood cell transfusion products. It currently has negative earnings. The company's INTERCEPT Blood Systems for platelets and plasma are designed to inactivate blood-borne pathogens in platelets and plasma donated for transfusion; and INTERCEPT Blood System for red blood cells to inactivate blood-borne pathogens in red blood cells donated for transfusion.

Cerus Corporation (NASDAQ:CERS) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.